

# Heme Malignancy Disease-Oriented Team

---

## Clinical Research Treatment Trial Flowchart

### Clinical Research Managers:

Stephanie Osorio  
Judit Castellanos

### Clinical Research Coordinators:

Alice Ting  
Michael Kunicki  
Kelsey McAbee  
Harleen Mehrok  
Georgina Alvarez-Diaz  
Melisa Duvnjak  
Makena Castillo

### Data Coordinators:

Heather Franson  
Mario Diaz  
Sarahy Martinez

Newly diagnosed

Open to Accrual Low Accruing Pending Activation/Suspended

Front Line

UCI 24-121

ASTX030 in Subjects w/Myeloid Neoplasm or in Combo w/Venetoclax in Subjects w/AML or MDS

Accrual: 1/5

Coord: Georgina Alvarez-Diaz

ETCTN 10675

A Randomized Phase II Trial of ASTX727 +/- ladamostat in Accelerated/Blast-Phase Philadelphia Chromosome-Negative Myeloproliferative Neoplasms (MPNs)

Accrual: 0/5

Coord: TBA

Supportive Care

UCI 20-50

N-Acetylcysteine in MPN to Improve Disease Markers & Symptoms

Accrual 14/27

Coord: Kelsey McAbee

UCI 26-12

A Phase 3 Randomized, Double-blind, Placebo-controlled Global Study of Sapablursen in Polycythemia Vera

Accrual:0

Coord: Michelle Andrade

**Newly diagnosed****UCI 24-121**

ASTX030 in Subjects  
w/Myeloid Neoplasm or in  
Combo w/Venetoclax in  
Subjects w/AML or MDS

Accrual: 1/5

Coord: TBD

**High-Risk****MM1MDS-A01**

A Randomized Phase II Trial  
of Enasidenib-Based  
Therapies Versus  
Cedazuridine-Decitabine in  
Higher-Risk IDH2-Mutated  
Myelodysplastic Syndrome: A  
MyeloMATCH Sub-Study

Accrual: 0/5

Coord: Georgina Alvarez-Diaz

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Low-Risk

Molecularly-Driven

HSCT

## Relapsed/Refractory

### Low-Risk

#### UCI 21-239

IRAK 1/4 inhibitor, R289, in patients w/ refractory or resistant lower-risk MDS

Accrual: 2/5

Coord: Georgina Alvarez-Diaz

#### UCI 25-193

ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies

Accrual: 0/7

Coord: TBD

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

### Molecularly-Driven

### High-Risk

## Newly diagnosed

### Intensive

#### ETCTN-10596

SNDX-5613 + Daunorubicin and Cytarabine in Newly Diagnosed Acute Myeloid Leukemia (NPM1 Mutated/FLT3 Wildtype with Higher-Risk Features or MLL/KMT2A Rearranged)

Accrual: 0/5

Coord: Stephanie Osorio

#### MYELOMATCH

MYELOMATCH, Master Screening and Reassessment Protocol (MSRP) for Tier Advancement in the NCI MyeloMATCH Clinical Trials

Accrual: 0/5

Coord: Georgina Alvarez-Diaz

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

### Non-Intensive

#### KMT2A-r/NPM1-m

#### UCI 23-44

Venetoclax/Azacitidine v.s Venetoclax+ KO-530 v.s cytarabine/daunorubicin (7+3)+ KO-539 in AML

Accrual: 9/10

Coord: Georgina Alvarez-Diaz

#### FLT3 mutation

#### UCI 21-216 (suspended)

Gilteritinib+Venetoclax+Azacitidine in patients w/ FLT3 mutant AML not eligible for intensive induction chemotherapy

Accrual: 2/5

Coord: Stephanie Osorio

#### ETCTN-10630

Ladademstat in Combination with Venetoclax and Azacitidine in Patients with Post MDS Transformation to AML

Accrual: 2/7

Coord: Stephanie Osorio

#### UCI 24-121

ASTX030 in Subjects w/Myeloid Neoplasm or in Combo w/Venetoclax in Subjects w/AML or MDS

Accrual: 1/5

Coord: Georgina Alvarez-Diaz

#### UCI 22-81

HM43239 in patients w/ R/R AML

Accrual: 2/6

Coord: Georgina Alvarez-Diaz

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

KMT2A-r/NPM1-m

**UCI 25-20**

Assessing Ziftomenib in  
Combination with Either  
Standard of Care  
Nonintensive  
(Venetoclax+Azacitidine) or  
Intensive (7+3) Therapy in  
Patients with Untreated  
NPM1 Mutated or KMT2A  
Rearranged AML

Accrual: 0/5

Coord: Georgina Alvarez-Diaz

## Relapsed/Refractory

### 2<sup>nd</sup> Line+

#### UCI 22-81

HM43239 in patients w/ R/R AML

Accrual: 2/6

Coord: Georgina Alvarez-Diaz

#### UCI 24-48

DFP-10917+Venetoclax in R/R AML

Accrual: 5/5

Coord: Georgina Alvarez-Diaz

### ≤1 Line Only

#### UCI 25-105

LYT-200 in patients w/ R/R AML or high-risk MDS

Accrual: 0/5

Coord: Stephanie Osorio

### Non-Intensive

#### UCI 25-193

ICP-248 in Combination with Azacitidine for the Treatment in Patients with Myeloid Malignancies

Accrual: 0/5

Coord: TBD

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Molecularly-Driven

## Relapsed/Refractory

■ Open to Accrual  
 ■ Low Accruing  
 ■ Pending Activation/Suspended

### Molecularly-Driven

KMT2A-r/NPM1-m

#### UCI 23-44

Venetoclax/Azacitidine v.s  
 Venetoclax+ KO-530 v.s  
 cytarabine/daunorubicin (7+3)+  
 KO-539 in AML

Accrual: 9/10

Coord: Georgina Alvarez-Diaz

#### UCI 23-154

Ziftomenib combinations for  
 the KMT2A-rearranged/NPM1  
 mutant R/R AML

Accrual: 3/5

Coord: Georgina Alvarez-Diaz

Maintenance

High-Risk, HSCT

Salvage Therapy

## Newly diagnosed

■ Open to Accrual  
 ■ Low Accruing  
 ■ Pending Activation/Suspended

### Ph+ only

#### EA9181

Steroids +TKI w/  
chemotherapy or  
Blinatumomab for BCR-ABL  
positive adult patients

Accrual 14/35

Coord: Judit Castellanos

#### SWOG-21CTP-LEUK01

Phase II Trial of Asciminib,  
Dasatinib, Prednisone, and  
Blinatumomab for Participants  
with Newly Diagnosed  
Philadelphia Chromosome  
Positive (PH+) Acute  
Lymphoblastic Leukemia

Accrual: 0/5

Coord: Stephanie Osorio/Judit  
Castellanos

### Ph- only

Age 5 to <30 years & High Risk ALL

Age ≥ 18 years & < 40 years,  
CD22+ (≥ 20%)

#### A041501 (SUSPENDED)

Addition of Inotuzumab  
Ozogamicin to frontline  
therapy in young adults (18-  
39y/o)

Accrual: 10/15

Coord: Judit Castellanos

#### UCI 25-104

subcutaneous blinatumomab  
vs. intravenous blinatumomab  
in newly diagnosed adults with  
(Ph)- B cell precursor ALL

Accrual: 0/5

Coord: TBD

## Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

## Molecularly-Driven

CR w/ MRD+

CD22+ ( $\geq 20\%$ )**A041703 (SUSPENDED)**

Inotuzumab Ozogamicin followed by  
Blinatumomab for ph- CD22-positive  
newly diagnosed or R/R ALL patients

Accrual: 2/5 (only open for R/R)

Coord: Judit Castellanos



# Newly diagnosed

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended

**UCI 25-166**

QTX-2101 in Newly Diagnosed  
Acute Promyelocytic Leukemia

Accrual: 0/5

Coord: TBA

## Newly diagnosed

### UCI 23-189

Frontline Ruxolitinib with De-Intensified HLH-94 for Adults with Hemophagocytic Lymphohistiocytosis (HLH)

Accrual: 0/6

Coord: Harleen Mehrok

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended



# Relapsed/Refractory

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended

2<sup>nd</sup> Line+

UCI 23-167

Phase I- TERN-701 in patients  
w/CML

Accrual: 2/5

Coord: Kelsey McAbee

Newly Diagnosed

■ Open to Accrual  
 ■ Low Accruing  
 ■ Pending Activation/Suspended

**UCI 24-170**

Intravenous Gammagard Liquid (Immune Globulin Infusion, 10%) for Primary Infection Prophylaxis Compared With Secondary Infection Prophylaxis in Adult Subjects With Multiple Myeloma Receiving B-Cell Maturation Antigen×CD3–Directed Bispecific Antibody Therapy  
 Accrual: 0/8

Coord: Alice Ting

**UCI 25-221**

A Phase III, Multicentre Study to Evaluate Consolidation Treatment with AZD0120 vs ASCT, in Participants with Newly Diagnosed Multiple Myeloma who are Transplant Eligible

Accrual: 0/999

Coord: Stephanie Osorio

Front Line

Post ASCT

Bispecific

High-Risk

**UCI 23-158 (suspended)**

Phase I/II Study of Linvoseltamab (Anti-BCMA X Anti-CD3 Bispecific Antibody) in Previously Untreated Patients with Symptomatic Multiple

**UCI 25-220**

A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120 Compared with Continuous Standard Therapy in Participants with NDMM Who Are Not Planned to Receive ASCT as Initial Therapy

Accrual: 0/5

Coord: Stephanie Osorio



# Newly Diagnosed

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended

**UCI 25-220**  
A Phase III Open-Label, Randomised, Multicentre Study of Consolidation with a Single Administration of AZD0120 Compared with Continuous Standard Therapy in Participants with NDMM Who Are Not Planned to Receive ASCT as Initial Therapy

Accrual: 0/5

Coord: Stephanie Osorio

## Relapsed/Refractory

**UCI 25-116**

ANTITUMOR ACTIVITY OF  
SIM0500, IN PARTICIPANTS  
WITH R/R MULTIPLE MYELOMA  
Accrual: 0/5

Coord: TBD

**UCI 24-170**

Intravenous Gammagard Liquid  
(Immune Globulin Infusion, 10%)  
for Primary Infection Prophylaxis  
Compared With Secondary  
Infection Prophylaxis in Adult  
Subjects With Multiple Myeloma  
Receiving B-Cell Maturation  
Antigen×CD3-Directed Bispecific  
Antibody Therapy  
Accrual: 0/8

Coord: Alice Ting

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

Molecularly-Driven

3<sup>rd</sup> Line+**UCI 25-62**

EXPANDED ACCESS PROTOCOL  
(EAP) FOR SUBJECTS RECEIVING  
IDECABTAGENE VICLEUCEL  
THAT IS NONCONFORMING FOR  
COMMERCIAL RELEASE

Accrual: 0/5

Coord: TBD

**ALLIANCE-A062102**

Iberdomide Maintenance Therapy  
Following Idecabtagene Vicleucel  
CAR-T in R/R MM  
Accrual: 0/5

Coord: Judit Castellanos

**UCI 26-07**

Phase 3 Randomized Study Comparing JNJ-  
79635322 versus Teclistamab in  
Participants with Relapsed or Refractory  
Multiple Myeloma who Have Received 1-3  
Prior Lines of Therapy

Accrual: 0

Coord: Michelle Andrade

2<sup>nd</sup> Line+

Maintenance

Trial Flowchart Jan\_2026

16

Newly diagnosed

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

**S1918 (SUSPENDED)**

R-miniCHOP w/ or w/o oral Azacitidine  
in patients 75 y/o or older

Accrual: 5/10

Coord: Melisa Duvnjak

**UCI 23-19 (suspended)**

PhIII Odronextamab Comb w/CHOP vs  
Rituximab Comb w/CHOP

Accrual: 0/5

Coord: Melisa D.

**UCI 24-22**

Loncastuximab Tesirine and Rituximab  
(Lonca-R) Followed by DA-EPOCH-R in  
Previously Untreated High-risk Diffuse  
Large B-cell Lymphoma

Accrual: 0/5

Coord: TBD

# Relapsed/Refractory

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended

## Primary Relapsed/Refractory

## Secondary Relapsed/Refractory

**UCI 20-126 (suspended)**  
 CB-010, CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy  
 Accrual: 7/10  
 Coord: Michael K.

## Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Molecularly-Driven

## Tertiary Relapsed/Refractory

**S2114**Consolidation therapy  
following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Michael Kunicki

## 2+ Lines

**UCI 24-12 (suspended)**Study to Evaluate the BTK Degradar,  
ABBV-101, in Participants With B-cell  
Malignancies

Accrual: 1/5

Coord: Kelsey McAbee

**UCI 23-114**Safety and Efficacy of IMPT-314, a  
CD19/20 Bispecific Chimeric Antigen  
Receptor (CAR) T Cell Therapy in B-cell  
NHL

Accrual: 7/10

Coord: Michale Kunicki

Newly diagnosed

Low Grade

**SWOG S2308**  
MOSUNETUZUMAB VS.  
RITUXIMAB FOR LOW TUMOR  
BURDEN FOLLICULAR  
LYMPHOMA

Accrual: 0/5

Coord: Harleen Mehrok

≥75 years

**S1918 (SUSPENDED)**  
R-miniCHOP w/ or w/o oral  
Azacitidine in patients 75 y/o or  
older

Accrual: 5/10

Coord: Melisa Duvnjak

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended

# Relapsed/Refractory

■ Open to Accrual  
 ■ Low Accruing  
 ■ Pending Activation/Suspended

## 2nd Line+

### UCI 22-134

Oral AS-1763 in patients w/  
previously treated CLL/SLL or  
NHL

Accrual: 5/9

Coord: Kelsey McAbee

## 3rd Line+

### UCI 24-12

BTK Degradar ABBV-101 in  
Pts w/ B-cell Malignancies

Accrual: 1/5

Coord: Kelsey McAbee

## Consolidation

### S2114

Consolidation therapy  
following CD19 CAR T-cell tx

Accrual: 0/6

Coord: Michael Kunicki

## Maintenance

### UCI 21-95

Acalabrutinib Maintenance  
Following Cellular Therapy for  
LBCL Patients at High Risk for  
Relapse

Accrual: 0/5

Coord: Michael Kunicki



# Relapsed/Refractory

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended

## Cell Therapy

### UCI 20-126 (suspended)

CB-010, CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy

Accrual: 7/10

Coord: Michael K.

### UCI 23-114

Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL

Accrual: 7/7

Coord: Michael Kunicki

### UCI 25-63

EAP for Lisocabtagene Maraleucel (liso-cel) that is Nonconforming for Commercial Release

Accrual: 0/5

Coord: TBD

### UCI 25-70

Ph III of LYL314 in 2L for R/R B-Cell NHL

Accrual: 0/3

Coord: Michael K.

# Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Cell Therapy

Molecularly-Driven

3<sup>rd</sup> Line+

### UCI 22-134

Oral AS-1763 in patients w/  
previously treated CLL/SLL or NHL

Accrual: 5/9

Coord: Kelsey McAbee

2+ Lines

### UCI 24-12 (suspended)

Study to Evaluate the BTK  
Degradar, ABBV-101, in  
Participants With B-cell  
Malignancies

Accrual: 1/5

Coord: Kelsey McAbee

# Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

EBV+

Molecularly-Driven

## 2 + Lines

### UCI 24-12 (suspended)

Study to Evaluate the BTK Degradar, ABBV-101, in Participants With B-cell Malignancies

Accrual: 1/5

Coord: Kelsey McAbee

## 3<sup>rd</sup> Line+

### UCI 22-134

Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 5/9

Coord: Kelsey McAbee

## Newly diagnosed

■ Open to Accrual
 ■ Low Accruing
 ■ Pending Activation/Suspended

## High-Risk

**S1925**

Venetoclax+Obnutumab early intervention vs. delayed therapy in asymptomatic high-risk CLL/SLL

Accrual: 4/10

Coord: Michael Kunicki

## Front Line

**UCI 25-192**

Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared with Venetoclax Plus Acalabrutinib in Patient with Previously Untreated CLL

Accrual: 0/7

Coord: TBD

## Follow Up

**UCI 25-205**

Long-term follow-up of ibrutinib plus venetoclax in patients with treatment-naïve CLL/SLL

Accrual: 0/7

Coord: TBD

## Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

3<sup>rd</sup> Line+**UCI 22-134**

Oral AS-1763 in patients w/  
previously treated CLL/SLL or NHL

Accrual: 5/9

Coord: Kelsey McAbee

**UCI 24-12**

Study to Evaluate the BTK Degradar,  
ABBV-101, in Participants With B-cell  
Malignancies

Accrual: 1/5

Coord: Kelsey McAbee

2<sup>nd</sup> Line+**UCI 24-190**

A Phase III Study of Sonrotoclax Plus  
Anti-CD20 Antibody Therapies Versus  
Venetoclax + Rituximab in Patients With  
R/R CLL/SLL

Accrual: 0/7

Coord: Kelsey McAbee

**UCI 24-32**

Epcoritamab as Consolidation Therapy  
for High-risk Patients with Chronic  
Lymphocytic Leukemia on Bruton  
Tyrosine Kinase Inhibitor

Accrual: 0/24

Coord: TBD

**UCI 25-04**

A Phase I/II, multicenter study  
evaluating point-of-care manufactured  
GLPG5101 (19CP02) in subjects with  
R/R B-cell non-Hodgkin lymphoma  
(CP0201NHL)

Accrual: 0/5

Coord: TBD

**UCI 25-148**

IgPro20 in Subjects with Chronic  
Lymphocytic Leukemia / Small  
Lymphocytic Lymphoma and  
Secondary Hypogammaglobulinemia  
Experiencing Severe or Recurrent  
Infections

Accrual: 0/5

Coord: TBD

Newly diagnosed

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended

Relapsed/Refractory

■ Open to Accrual   
 ■ Low Accruing   
 ■ Pending Activation/Suspended

Molecularly-Driven

Consolidation

**S2114**

Consolidation therapy following  
CD19 CAR T-cell tx

Accrual: 0/6

Coord: Michael Kunicki

2+ Lines

**UCI 24-12 (Suspended)**

Study to Evaluate the BTK  
Degradar, ABBV-101, in  
Participants With B-cell  
Malignancies

Accrual: 1/5

Coord: Kelsey McAbee

# Relapsed/Refractory

■ Open to Accrual   
 ■ Low Accruing   
 ■ Pending Activation/Suspended

## Molecularly-Driven

### Cell Therapy

#### UCI 23-114

Safety and Efficacy of IMPT-314, a CD19/20 Bispecific Chimeric Antigen Receptor (CAR) T Cell Therapy in B-cell NHL

Accrual: 7/10

Coord: Michael Kunicki

### 2+ Lines

#### UCI 24-12 (Suspended)

Study to Evaluate the BTK Degradator, ABBV-101, in Participants With B-cell Malignancies

Accrual: 1/5

Coord: Kelsey McAbee

### 3<sup>rd</sup> line+

#### UCI 22-134

Oral AS-1763 in patients w/ previously treated CLL/SLL or NHL

Accrual: 5/9

Coord: Kelsey McAbee

#### UCI 24-174

Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Accrual: 0/5

Coord: Melisa Duvnjak

#### UCI 21-95

Acalabrutinib Maintenance Following Cellular Therapy for LBCL Patients at High Risk for Relapse

Accrual: 0/5

Coord: Michael Kunicki

## Relapsed/Refractory

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

2<sup>nd</sup> Line+**UCI 21-99**

ONO-4685 given as  
monotherapy

Accrual: 4/10

Coord: Melisa Duvnjak

**UCI 24-188**

PHASE 2 STUDY OF PTX-100  
MONOTHERAPY IN PATIENTS  
WITH R/R CUTANEOUS T-CELL  
LYMPHOMA

Accrual: 0/5

Coord: Melisa Duvnjak

**UCI 25-74**

A Multicenter, Open-Label,  
First-In-Human, Multiple  
Expansion Cohort, Phase I/II  
Study to Evaluate the Safety and  
Efficacy of DR-01 in Subjects  
with LGLL or Cytotoxic  
Lymphomas

Accrual: 1/5

Coord: Melisa Duvnjak

**UCI 25-142**

Study of KK2223 in Participants  
with Relapsed or Refractory T-cell  
Non-Hodgkin Lymphoma

Accrual: 0/5

Coord: Judit Castellanos, Stephanie  
Osorio

## Relapsed/Refractory

### 1st Line+

#### UCI 25-142

Study of KK2223 in Participants with Relapsed or Refractory T-cell Non-Hodgkin Lymphoma

Accrual: 0/5

Coord: Judit Castellanos, Stephanie Osorio

### 3<sup>rd</sup> Line+

#### UCI 21-99

ONO-4685 given as monotherapy

Accrual: 4/10

Coord: Melisa Duvnjak

#### UCI 24-174

Efficacy and Safety of ITK Inhibitor Soquelitinib Versus Physician's Choice Standard of Care Treatment (Selected Single Agent) in Participants with Relapsed/Refractory Peripheral T-cell Lymphoma Not Otherwise Specified, Follicular Helper T-cell Lymphomas, or Systemic Anaplastic Large-cell Lymphoma

Accrual: 0/5

Coord: Melisa Duvnjak

#### ECOG EA4232

Phase III Study to Evaluate Autologous Stem Cell Transplant in Patients with Peripheral T Cell Lymphoma that Achieved a First Complete Remission (CR1) Following Induction Therapy (PTCL-STAT)

Accrual: 0/5

Coord: Judit Castellanos, Stephanie Osorio

## Newly Diagnosed

#### UCI 22-18

Investigation of MRD in patients with treatment-naive systemic T cell lymphoma treated with a brentuximab-containing regimen

Accrual: 0/5

Coord: Judit Castellanos, Stephanie Osorio



**UCI 25-74**

A Multicenter, Open-Label, First-In-Human, Multiple Expansion Cohort, Phase I/II Study to Evaluate the Safety and Efficacy of DR-01 in Subjects with LGLL or Cytotoxic Lymphomas

Accrual: 1/5

Coord: Melisa Duvnjak



## Newly Diagnosed

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended

### COG-AHOD2131

Standard Therapy with  
Immuno-oncology Therapy  
for Newly Diagnosed Stage I  
and II Classical Hodgkin  
Lymphoma

Accrual: 1/5

Coord: Melisa Duvnjak

## Relapsed/Refractory

≥ 1 Line

## UCI 25-21

Pembrolizumab and GVD with  
ctDNA-guided Consolidation in  
Patients with Relapsed or  
Refractory Classic Hodgkin  
Lymphoma

Accrual: 0/5

Coord: Judit Castellanos,  
Stephanie Osorio

■ Open to Accrual

■ Low Accruing

■ Pending Activation/Suspended

Molecularly-Driven

Basket study

# CAR-T Products

## Allogeneic CAR-T

### NHL

#### UCI 20-126 (Suspended)

CB-010, CRISPR-edited allogeneic anti-CD19 CAR-T cell therapy

Accrual: 7/10

Coord: Michael K.

#### UCI 25-209

Study to evaluate the safety, expansion, persistence and clinical activity of UCART22 (allogeneic engineered T-cells expressing Anti-CD22 Chimeric Antigen Receptor) in patients with relapsed or refractory CD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)

Accrual: 0/3

Coord: Stephanie Osorio

■ Open to Accrual  
 ■ Low Accruing  
 ■ Pending Activation/Suspended

## Autologous CAR-T

### NHL

#### UCI 23-114

Safety & Efficacy of LYL314, a CD19/20 Bispecific CAR-T for R/R B-Cell NHL

Accrual: 7/10

Coord: Michael K.

#### UCI 25-70

Ph III of LYL314 in 2L for R/R B-Cell NHL

Accrual: 0/3

Coord: Michael K.

#### UCI 25-63

EAP for Lisocabtagene Maraleucel (liso-cel) that is Nonconforming for Commercial Release

Accrual: 0/999

Coord: Judit Castellanos, Stephanie Osorio

### MM

#### UCI 25-63

EAP for Vicleucel (ide-cel) that is Nonconforming for Commercial Release

Accrual: 0/999

Coord: Judit Castellanos, Stephanie Osorio

### Other

#### UCI 24-152

NXC-201 for the Treatment of Patients w/ R/R AL Amyloidosis

Accrual: 0/10

Coord: Michael K.

# Supportive Care

■ Open to Accrual  
 ■ Low Accruing  
 ■ Pending Activation/Suspended

## Autologous

### UCI 23-193

CTO1681 for the Prevention & Treatment of CRS in pts w/ DLBCL receiving CAR-T Therapy

Accrual: 1/5

Coord: Judit Castellanos

### Alliance-A062102

Iberdomide Maintenance Therapy Following Ide-Cel CAR-T in R/R Multiple Myeloma

Accrual: 0/5

Coord: Michael K.

### S2114

Consolidation Therapy Following CD19 CAR-T for R/R Large B-cell Lymphoma or Grade IIIB Follicular Lymphoma

Accrual: 0/6

Coord: Michael Kunicki

### UCI 24-110

HaploDonor-QoL: Donor Health-Related Quality-of-Life and Physician Decision-Making in the Context of Haploidentical Hematopoietic Stem Cell Transplantation

Accrual: 0/7

Coord: Mario Diaz

## Allogeneic

### UCI 21-90

Risk-ADAPTEd conditioning regimen for AHSCT

Accrual: 29/48

Coord: Mario Diaz

### UCI 22-188

Prospective evaluation of CMV-TCIP directed Letemovir ppx after AHCT

Accrual: 16/50

Coord: Mario Diaz

### UCI 24-131

Vimseltinib in Adults With Active Chronic GVHD After Failure of Prior Systemic Therapy

Accrual: 0/5

Coord: Mike K.

### UCI 25-139

Efficacy of SER-155 to Reduce Bloodstream Infections in Adults Undergoing Allogeneic Hematopoietic Cell Transplantation

Accrual: 0/5

Coord: Judit Castellanos, Stephanie Osorio



## LTFU

### UCI 21-184

Long-term safety of CAR-T  
inpatient w/ heme malignancies

Accrual: 6/7

Coord: Michael Kunicki

### UCI 24-31

Long-Term Follow-up Protocol for  
Subjects Treated With Gene-Modified T  
Cells

Accrual: 0/5

Coord: Judit Castellanos, Stephanie  
Osorio

■ Open to Accrual   ■ Low Accruing   ■ Pending Activation/Suspended



# Other

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

## UCI 15-65

Effect of candidate blood cancer therapies on normal human lymphocytes

## UCI 24-110

HaploDonor-QoL: Donor Health-Related Quality-of-Life and Physician Decision-Making in the Context of Haploidentical Hematopoietic Stem Cell Transplantation

Accrual: 0/7

Coord: Mario Diaz

## UCI 14-89

Hematologic Malignancies Biorepository for human research

Accrual: 321/500

Coord: Helen Huang

## UCI 22-194

A Retrospective analysis of L-carnitine for Treatment and/or Prevention of L-Asparaginase Hepatotoxicity during Induction or Salvage Chemotherapy for Hematologic Malignancies

Accrual: 0/999

Coord: Emiri Matsuda

## UCI 25-195

A prospective randomized basket trial evaluating the clinical utility of plasma-based microbial cell-free metagenomic sequencing for diagnosis and management of suspected infections in adult immunocompromised Outpatients

Accrual: 0/10

Coord: Stephanie Osorio

## UCI 25-226

PROSPECTIVE OBSERVATIONAL INTERNATIONAL REGISTRY OF PATIENTS WITH NEWLY DIAGNOSED BURKITT LYMPHOMA

Accrual: 0/5

Coord: Stephanie Osorio

## UCI 25-198

A multicenter protocol for haploidentical stem cell transplantation: Optimization of transplant outcomes in a collaborative consortium

Accrual: 0/999

Coord: Stephanie Osorio



## Other

■ Open to Accrual ■ Low Accruing ■ Pending Activation/Suspended

### S2213

A Phase III, Randomized Study of Daratumumab, Cyclophosphamide, Bortezomib and Dexamethasone (Dara-VCD) Induction Followed by Autologous Stem Cell Transplant or Dara-VCD Consolidation and Daratumumab Maintenance in Patients with Newly Diagnosed AL Amyloidosis  
Accrual: 0/999  
CRC: Stephanie Osorio